Fischer Medical Ventures Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,735 Cr
- P/E
- 70.85
- ROE
- 8.91%
- PEG
- 0.09
- Price to sales
- 4.72
- Debt to equity
- 0.28
- 52W high / low
- ₹118 / ₹23.9
- EBITDA margin
- 12.34%
- Net profit margin
- 10.06%
- Promoter holding
- 63.09%
- Sales (last year)
- ₹367 Cr
Fischer Medical Ventures Ltd, earlier known as Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam.[1]
Guidance scorecard · Q1 FY27 call
What Fischer Medical Ventures Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ2 FY26 call
10–20%- Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies.
- The total addressable market (TAM) for MRI devices in India is around 500 units per year, expected to grow over 1000 units annually in 3-4 years, driven by government health missions.
- Growth is expected to be broad-based across Radiology (MRI and CT) and Preventive Healthcare segments, with revenue contribution expected to be almost equally split between these two in 2-3 years.
- Company aims to leverage Make-In-India and Atmanirbhar Bharat initiatives along with import substitution to drive growth aligned with sector CAGR of 15%-20%.
2 more points from Fischer Medical Ventures Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY26 call
FlatSee what Fischer Medical Ventures Ltd said on margins — free account, 30 seconds.
CapexQ2 FY26 call
Planned- Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts.
- Facility expansion plans underway: Expansion of manufacturing facility to include other imaging lines such as CT scanners.
- Preventive healthcare capacity expansion: Focus on people (AI, software development) and server infrastructure rather than hardware manufacturing.
2 more points from Fischer Medical Ventures Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY26 call
See what Fischer Medical Ventures Ltd said on fundraising — free account, 30 seconds.
Order bookQ2 FY26 call
Rising- Fischer Medical Ventures has a strong order book currently.
- Orders are being fulfilled as and when they arise, especially in the MRI segment.
- The sales cycle for MRI machines ranges from 6 to 9 months, sometimes up to 12 months.
2 more points from Fischer Medical Ventures Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Fischer Medical Ventures Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Fischer Medical Ventures Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Fischer Medical Ventures Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 |
| Expenses + | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 |
| Operating Profit | 0 | 3 | -0 | 0 | 0 | 2 | 4 | 16 | 22 |
| OPM % | 12% | -2% | 1% | 3% | 5% | 18% | 19% | 21% | |
| Other Income + | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 |
| Tax % | 6% | 271% | -38% | 350% | 28% | 51% | 19% | 9% | |
| Net Profit + | 0 | 3 | -0 | 0 | -0 | 1 | 5 | 14 | 19 |
| EPS in Rs | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.02 | 0.08 | 0.21 | 0.30 |
Financials of Fischer Medical Ventures Ltd
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| Sales + | 0 | 21 | 111 | 260 |
| Expenses + | 0 | 19 | 108 | 216 |
| Operating Profit | 0 | 2 | 3 | 44 |
| OPM % | 11% | 9% | 3% | 17% |
| Other Income + | 0 | 0 | 1 | 11 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | 0 | 0 | 2 | 3 |
| Profit before tax | 0 | 2 | 2 | 50 |
| Tax % | 13% | 45% | ||
| Net Profit + | -0 | 2 | 1 | 39 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.61 |
| Dividend Payout % | 0% | 0% | 22% |
Financials of Fischer Medical Ventures Ltd
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | -0 | 28 | 274 | 295 |
| Borrowings + | 1 | 2 | 85 | 30 |
| Other Liabilities + | 0 | 4 | 34 | 77 |
| Total Liabilities | 0 | 86 | 457 | 468 |
| Fixed Assets + | 0 | 15 | 24 | 31 |
| CWIP | 0 | 0 | 1 | 2 |
| Investments | 0 | 1 | 11 | 121 |
| Other Assets + | 0 | 70 | 421 | 313 |
| Total Assets | 0 | 86 | 457 | 468 |
Financials of Fischer Medical Ventures Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Cash from Operating Activity + | -7 | -87 | |
| Cash from Investing Activity + | -29 | -125 | |
| Cash from Financing Activity + | 37 | 315 | |
| Net Cash Flow | 1 | 103 | |
| Free Cash Flow | -8 | -93 | |
| CFO/OP | -392% | -3,001% |
Financials of Fischer Medical Ventures Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 345 | 398 | 251 |
| Inventory Days | 99 | 36 | |
| Days Payable | 48 | 82 | |
| Cash Conversion Cycle | 345 | 449 | 205 |
| Working Capital Days | 324 | 498 | 40 |
| ROCE % | 5% | 1% |
Momentum score · price trend
1 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −78.8% | 0% |
| Last 6 months | −34.7% | 6% |
| Last 3 months | −36.6% | 2% |
The price is 78.9% below its all-time high of ₹117.71 (31 Oct 2025). Stocks more than 20% below their peak have their score halved, so 3 became 1.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Fischer Medical Ventures Ltd: 0.4 × 0 + 0.4 × 6 + 0.2 × 2 = 3, halved to 1 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Fischer Medical Ventures Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec